Rotenone in Mitochondrial Proteostasis and Metabolic Signaling

Introduction

Mitochondrial dysfunction is central to the pathogenesis of numerous neurodegenerative diseases and metabolic syndromes. The use of mitochondrial Complex I inhibitors such as Rotenone (CAS 83-79-4) has become fundamental in dissecting the pathways underlying cell death, energy failure, and redox imbalance. Beyond its established role as a toxin and research tool, rotenone is increasingly leveraged to interrogate the crosstalk between mitochondrial electron transport, proteostasis, and metabolic signaling. Recent advances, including the identification of post-translational regulatory mechanisms affecting mitochondrial enzymes (Wang et al., Molecular Cell, 2025), provide new context for interpreting data obtained from rotenone-based models.

Rotenone: Mechanism of Action and Research Utility

Rotenone is a naturally derived mitochondrial Complex I inhibitor with an IC₅₀ of 1.7–2.2 μM. By blocking electron transfer within NADH:ubiquinone oxidoreductase (Complex I), it impedes the formation of the mitochondrial proton gradient, suppressing ATP synthesis via oxidative phosphorylation. This leads to the accumulation of NADH, increased generation of mitochondrial reactive oxygen species (ROS), and profound metabolic stress. As a result, rotenone serves as a prototypical mitochondrial dysfunction inducer in both cellular and animal research settings.

In differentiated SH-SY5Y neuroblastoma cells, rotenone acts as a potent apoptosis inducer and impairs mitochondrial trafficking, with well-characterized biphasic survival responses at nanomolar concentrations. In vivo, intranasal rotenone administration models Parkinson’s disease by selectively triggering dopaminergic neurite degeneration in the substantia nigra and compromising olfactory function. These properties establish rotenone as a cornerstone tool for neurodegenerative disease research, enabling the study of apoptosis, autophagy pathway activation, and ROS-mediated cell death, as well as the interrogation of stress-responsive signaling cascades such as p38 MAPK and JNK.

Proteostasis and Post-Translational Regulation in Mitochondria

The functional integrity of mitochondria is not solely dictated by metabolic flux but also by the homeostasis of its constituent proteins (proteostasis). Protein folding, assembly, and regulated degradation are orchestrated by an intricate network of chaperones, co-chaperones, and proteases. Disruption of these systems by genetic or chemical perturbations—including exposure to mitochondrial toxins such as rotenone—can precipitate maladaptive responses, culminating in cell death or disease phenotypes.

Recent research by Wang et al. (2025) provides critical insight into post-translational regulation within mitochondria. The study characterizes TCAIM, a DNAJC-type co-chaperone, as a selective interactor of the OGDH subunit of the α-ketoglutarate dehydrogenase complex (OGDHc). Rather than facilitating protein folding, TCAIM collaborates with mitochondrial HSP70 (HSPA9) and the Lon protease (LONP1) to reduce OGDH levels, thereby attenuating OGDHc activity and altering mitochondrial metabolism. This noncanonical regulatory axis offers a new dimension for understanding how mitochondrial metabolic output is fine-tuned, particularly under stress conditions such as those induced by rotenone.

Applications of Rotenone in Investigating Mitochondrial Proteostasis

While rotenone is primarily recognized as a mitochondrial Complex I inhibitor, its broader effects on mitochondrial homeostasis and signaling have become increasingly relevant. By impairing electron transport and elevating ROS production, rotenone generates a cellular context in which proteostatic stress is amplified. This scenario is ideal for dissecting the interplay between mitochondrial dysfunction, protein quality control, and metabolic adaptation.

For example, rotenone-induced oxidative stress promotes the misfolding or oxidative modification of mitochondrial proteins, which in turn activates chaperone-mediated responses and proteolytic degradation. In the context of the findings by Wang et al., researchers can leverage rotenone models to examine how perturbations in proteostasis—such as those mediated by the TCAIM/HSPA9/LONP1 axis—modulate the stability and function of critical metabolic enzymes like OGDHc. This is especially pertinent for experiments aiming to link metabolic flux, ROS-mediated cell death, and the activation of stress-responsive MAP kinase signaling pathways, including p38 MAPK and JNK.

Moreover, rotenone can serve as a tool to evaluate the efficacy of caspase activation assays and to probe the induction of autophagy, both of which are tightly intertwined with mitochondrial health. The compound’s documented effects on apoptosis in SH-SY5Y neuroblastoma cells make it a gold-standard reagent for mechanistic studies of cell death pathways.

Experimental Considerations and Practical Guidance

When utilizing rotenone for mitochondrial and proteostasis research, several technical aspects must be considered to ensure experimental rigor and reproducibility:

• Solubility and Handling: Rotenone is insoluble in ethanol and water but dissolves readily in DMSO at concentrations ≥77.6 mg/mL. Stock solutions should be freshly prepared and stored below -20°C, minimizing freeze-thaw cycles to preserve potency.
• Concentration Selection: For apoptosis induction in SH-SY5Y cells, concentrations as low as 50 nM can elicit effects over extended culture periods, while higher micromolar concentrations are typically required for acute mitochondrial inhibition in diverse cell types.
• Model Selection: In animal models, delivery routes (e.g., intranasal vs. systemic) and dosing regimens must be tailored to the desired pathology, such as olfactory dysfunction or nigrostriatal degeneration relevant to Parkinson’s disease modeling.
• Assay Readouts: Rotenone’s ability to induce ROS-mediated cell death and activate caspase cascades makes it well-suited for use in caspase activation assays and autophagy pathway research. Coupling rotenone treatment with genetic or pharmacological modulation of chaperone/protease systems (e.g., TCAIM, HSPA9, LONP1) can further elucidate the role of proteostasis in mitochondrial stress responses.

Integrating Rotenone Models with Emerging Concepts in Mitochondrial Regulation

The study by Wang et al. (2025) underscores the importance of post-translational regulation of mitochondrial metabolic enzymes in cellular adaptation to stress. Rotenone-induced mitochondrial dysfunction provides a unique system in which to interrogate these regulatory processes. For instance, researchers can use rotenone to induce mitochondrial proteostatic stress and then assess the impact of TCAIM-mediated OGDH degradation on metabolic flux, ROS production, and cell survival under these conditions.

This approach is particularly valuable for unraveling the intersections between metabolic enzyme abundance, redox state, and the activation of MAP kinase pathways such as p38 MAPK and JNK, both of which are responsive to mitochondrial-derived signals. By pairing rotenone treatment with molecular tools (e.g., siRNA or CRISPR-based knockdown of TCAIM or LONP1), investigators can dissect the causal relationships between mitochondrial proteostasis, metabolic reprogramming, and cell fate decisions.

Future Directions in Mitochondrial Dysfunction and Neurodegenerative Disease Research

Building on foundational work with mitochondrial toxins, the field is moving toward an integrated understanding of how mitochondrial dysfunction, proteostasis, and metabolic signaling converge to drive neurodegenerative disease. Rotenone remains a versatile and indispensable reagent for these studies, particularly as new regulatory nodes—such as the TCAIM/HSPA9/LONP1 axis—are elucidated.

Future research will benefit from combining rotenone-based models with advanced proteomic, metabolomic, and genetic approaches to map the full spectrum of mitochondrial adaptive responses. Such endeavors hold promise for identifying novel therapeutic targets to restore mitochondrial function or mitigate the consequences of chronic proteostatic and metabolic stress in diseases such as Parkinson’s and Alzheimer’s.

Conclusion: Distinguishing This Perspective from Previous Work

While prior reviews such as "Rotenone: A Mitochondrial Complex I Inhibitor for Neurodegenerative Disease Research" have thoroughly characterized rotenone’s direct effects on electron transport and cell viability, the present article extends these foundations by integrating novel insights from the post-translational regulation of mitochondrial enzymes. Specifically, we highlight how rotenone-induced mitochondrial dysfunction serves as a model system for probing proteostatic networks—such as the TCAIM-mediated degradation of OGDH—and their impact on metabolic signaling and cell fate. By situating rotenone research at the intersection of electron transport, proteostasis, and metabolic adaptation, this piece provides practical guidance and a conceptual framework for exploring emerging mechanisms in mitochondrial biology.